z-logo
Premium
Phase Ib trial of the PI 3K/ mTOR inhibitor voxtalisib ( SAR 245409) in combination with chemoimmunotherapy in patients with relapsed or refractory B‐cell malignancies
Author(s) -
Awan Farrukh T.,
Gore Lia,
Gao Lei,
Sharma Jyoti,
Lager Joanne,
Costa Luciano J.
Publication year - 2016
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.14181
Subject(s) - bendamustine , medicine , rituximab , neutropenia , febrile neutropenia , tolerability , mantle cell lymphoma , gastroenterology , adverse effect , lymphoma , pharmacology , oncology , chemotherapy
This phase Ib, dose‐escalation study investigated the maximum tolerated dose ( MTD ), recommended phase II dose ( RP 2D), safety, pharmacokinetics ( PK ) and preliminary efficacy of the pan‐class I phosphoinositide 3‐kinase ( PI 3K) and mechanistic target of rapamycin ( mTOR ) inhibitor voxtalisib [30 or 50 mg twice daily ( BID )], in combination with rituximab (voxtalisib+rituximab) or rituximab plus bendamustine (voxtalisib+rituximab+bendamustine), in relapsed or refractory indolent B‐cell non‐Hodgkin lymphoma ( NHL ), mantle cell lymphoma and chronic lymphocytic leukaemia ( CLL ). MTD and RP 2D of voxtalisib were determined using a 3 + 3 dose‐escalation design. Adverse events ( AE s), plasma PK and disease response were recorded. Thirty‐seven patients were enrolled. The RP 2D of voxtalisib in combination with rituximab or rituximab+bendamustine was 50 mg BID . Four patients experienced a total of five dose‐limiting toxicities. The most frequent AE s were nausea (45·9%), fatigue (37·8%) headache (32·4%) and pyrexia (32·4%). The most frequent grade ≥3 AE s were neutropenia (27·0%), thrombocytopenia (24·3%), anaemia (16·2%) and febrile neutropenia (10·8%). Voxtalisib PK parameters were not affected by co‐administration with rituximab or rituximab+bendamustine. Of 35 efficacy‐evaluable patients, four (11·4%) achieved complete response and 13 (37·1%) achieved partial response. Voxtalisib, in combination with rituximab or rituximab+bendamustine, demonstrated an acceptable safety profile and encouraging anti‐tumour activity in relapsed or refractory B‐cell malignancies.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here